Page 6 - Indian Pharma Companies

We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Lessons from Maiden: Gambia deaths raise several questions

Pharma regulatory system needs re-examination. It's not just overseas buyers of Indian pharma products who are at potential risk. Counterfeit drugs remain a major threat in the domestic market

Maiden Pharmaceuticals breaks silence on cough syrup deaths in Gambia

The pharma company Maiden Pharmaceuticals has come under scanner after 66 children died in the Gambia after consuming cough syrup produced in India

WHO issues alert for 4 India-made cough syrups; check symptoms here

WHO has asked not to use these four products until analysed by the relevant national regulatory authorities

QR codes to soon be printed on medicines to check for their authenticity

In the first phase of the 'track and trace' mechanism, the QR codes will be printed on the primary packaging like the bottle, can, jar or the strip

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Indian pharma industry eyes South American market, seeks greater access

As Global pharma majors are exiting South America post Covid, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is looking to promote Indian pharmaceutical exports in the LAC

Govt launches 3 schemes to strengthen MSMEs in pharmaceutical sector

The government on Thursday launched three schemes to strengthen Micro, Small and Medium Enterprises (MSMEs) in the pharmaceutical sector. Union minister Mansukh Mandaviya noted that the schemes envisage technology upgradation, setting up of common research centres and effluent treatment plants in clusters for the pharma MSMEs. Small companies should be able to upgrade their facilities to global manufacturing standards, he said. The chemicals and fertilisers ministry rolled out the schemes under the banner of 'Strengthening Pharmaceuticals Industry' (SPI). "I believe the pharma MSME industry will greatly benefit from the schemes. The new schemes have many benefits that will go a long way in making the Indian pharmaceutical industry, Atma Nirbhar, more resilient and future-ready," Mandaviya, who heads both health as well as chemical and fertilisers ministries, said. The schemes provide for credit linked capital and interest subsidy for technology upgradation of MSME units in ...

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Cell-therapy treatment for cancer in India may come at 10% of US cost

Pharma firms and start-ups working to launch it within 2 yrs

Time for Indian pharma industry to move to value leadership: Mandaviya

Time has come for the Indian pharmaceuticals industry to move from 'volume' to 'value' leadership to capture global market and the government is committed to supporting companies with industry-friendly policies, Union minister Mansukh Mandaviya said on Saturday. Addressing an interactive session with Indian Pharmaceutical Alliance, the Minister for Chemicals & Fertilizers and Health & Family Welfare also asked the homegrown firms to learn from global best practices and develop own models to meet domestic demand while increasing international footprint. "Let us move from 'Volume' to 'Value' leadership to capture global pharmaceutical market," an official statement said, quoting Mandaviya. He further said, "It is time to accumulate knowledge from global best practices in research, manufacturing and innovation and develop our own models focused on accelerating production to meet the domestic demand while increasing our global footprint." The minister also pushed for making the .

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

Caring for patients runs in our DNA, say Cipla's Samina Hamied, Umang Vohra

'Cipla has so many capabilities that for anything we need to do, we say we can do it'

Dip in demand for Covid medicines takes a toll on drug sales in March

Covid related drugs contributed 40% of the pharma market last year

India's major drug players bet on new brand launches, shows data

Industry insiders say brand launches are the lifeline of the pharma industry, and ensure steady volume growth and market share

Alembic Pharma targets 10-12 product filings from Karkhadi facility

Resolution of the observations made by the USFDA (for which Alembic has already responded to the regulator) is critical for Alembic's US business

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Wockhardt sets issue price at Rs 225/share for Rs 748-cr rights issue

Earlier in January this year, Wockhardt's board had approved raising of up to Rs 1,000 crore through a rights issue to its existing shareholders